ArticleFrontiers in pharmacology2023

Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study.

Shanshan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.